IL-22 increases permeability of intestinal epithelial tight junctions by enhancing claudin-2 expression

Journal of Immunology

Volumn 199, Issue 9, 2017, Pages 3316-3325

  Wang, Yaya ^a   Mumm, John Brian ^a   Herbst, Ronald ^a   Kolbeck, Roland ^a   Wang, Yue ^a  

^a MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLAUDIN 2; INTERLEUKIN 22; JANUS KINASE; JANUS KINASE INHIBITOR; SMALL INTERFERING RNA; STAT PROTEIN; CLAUDIN; CLDN2 PROTEIN, HUMAN; CLDN2 PROTEIN, MOUSE; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22;

ARTICLE; CACO-2 CELL LINE; CELL ISOLATION; CELL VIABILITY; COLON EPITHELIUM; CONTROLLED STUDY; ELECTRIC RESISTANCE; EPITHELIUM CELL; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; INTESTINE EPITHELIUM; MALE; MEMBRANE PERMEABILITY; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA EXTRACTION; SIGNAL TRANSDUCTION; TIGHT JUNCTION; TRANSEPITHELIAL ELECTRICAL RESISTANCE; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; IMMUNOLOGY; INTESTINE MUCOSA; PERMEABILITY;

ANIMALS; CACO-2 CELLS; CLAUDINS; HUMANS; INTERLEUKINS; INTESTINAL MUCOSA; MALE; MICE; MICE, INBRED BALB C; PERMEABILITY; SIGNAL TRANSDUCTION; TIGHT JUNCTIONS; UP-REGULATION;

EID: 85032004783     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1700152     Document Type: Article

References (68)

1. Zihni, C., C. Mills, K. Matter, and M. S. Balda. 2016. Tight junctions: from simple barriers to multifunctional molecular gates. Nat. Rev. Mol. Cell Biol. 17: 564-580.
2. Gunzel, D., and A. S. Yu. 2013. Claudins and the modulation of tight junction permeability. Physiol. Rev. 93: 525-569.
3. Peterson, L. W., and D. Artis. 2014. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat. Rev. Immunol. 14: 141-153.
4. Lee, S. H. 2015. Intestinal permeability regulation by tight junction: implication on inflammatory bowel diseases. Intest. Res. 13: 11-18.
5. Lameris, A. L., S. Huybers, K. Kaukinen, T. H. Mäkelä, R. J. Bindels, J. G. Hoenderop, and P. I. Nevalainen. 2013. Expression profiling of claudins in the human gastrointestinal tract in health and during inflammatory bowel disease. Scand. J. Gastroenterol. 48: 58-69.
6. Lu, Z., L. Ding, Q. Lu, and Y. H. Chen. 2013. Claudins in intestines: distribution and functional significance in health and diseases. Tissue Barriers 1: e24978.
7. Barmeyer, C., J. D. Schulzke, and M. Fromm. 2015. Claudin-related intestinal diseases. Semin. Cell Dev. Biol. 42: 30-38.
8. Niessen, C. M. 2007. Tight junctions/adherens junctions: basic structure and function. J. Invest. Dermatol. 127: 2525-2532.
9. Hou, J., M. Rajagopal, and A. S. Yu. 2013. Claudins and the kidney. Annu. Rev. Physiol. 75: 479-501.
10. Yu, A. S., M. H. Cheng, S. Angelow, D. Gunzel, S. A. Kanzawa, E. E. Schneeberger, M. Fromm, and R. D. Coalson. 2009. Molecular basis for cation selectivity in claudin-2-based paracellular pores: identification of an electrostatic interaction site. J. Gen. Physiol. 133: 111-127.
11. Rosenthal, R., D. Gunzel, S. M. Krug, J. D. Schulzke, M. Fromm, and A. S. Yu. 2016. Claudin-2-mediated cation and water transport share a common pore. Acta physiol. 219: 521-536.
12. Muto, S., M. Hata, J. Taniguchi, S. Tsuruoka, K. Moriwaki, M. Saitou, K. Furuse, H. Sasaki, A. Fujimura, M. Imai, et al. 2010. Claudin-2-deficient mice are defective in the leaky and cation-selective paracellular permeability properties of renal proximal tubules. Proc. Natl. Acad. Sci. USA 107: 8011-8016.
13. Prasad, S., R. Mingrino, K. Kaukinen, K. L. Hayes, R. M. Powell, T. T. MacDonald, and J. E. Collins. 2005. Inflammatory processes have differential effects on claudins 2, 3 and 4 in colonic epithelial cells. Lab. Invest. 85: 1139-1162.
14. Zeissig, S., N. Burgel, D. Gunzel, J. Richter, J. Mankertz, U. Wahnschaffe, A. J. Kroesen, M. Zeitz, M. Fromm, and J. D. Schulzke. 2007. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. Gut 56: 61-72.
15. Oshima, T., H. Miwa, and T. Joh. 2008. Changes in the expression of claudins in active ulcerative colitis. J. Gastroenterol. Hepatol. 23(Suppl. 2): S146-S150.
16. Weber, C. R., S. C. Nalle, M. Tretiakova, D. T. Rubin, and J. R. Turner. 2008. Claudin-1 and claudin-2 expression is elevated in inflammatory bowel disease and may contribute to early neoplastic transformation. Lab. Invest. 88: 1110-1120.
17. Randall, K., N. Henderson, J. Reens, S. Eckersley, A. C. Nyström, M. C. South, C. A. Balendran, G. Böttcher, G. Hughes, and S. A. Price. 2016. Claudin-2 expression levels in ulcerative colitis: development and validation of an in-situ hybridisation assay for therapeutic studies. PLoS One 11: e0162076.
18. Schmitz, H., C. Barmeyer, M. Fromm, N. Runkel, H. D. Foss, C. J. Bentzel, E. O. Riecken, and J. D. Schulzke. 1999. Altered tight junction structure contributes to the impaired epithelial barrier function in ulcerative colitis. Gastroenterology 116: 301-309.
19. Heller, F., P. Florian, C. Bojarski, J. Richter, M. Christ, B. Hillenbrand, J. Mankertz, A. H. Gitter, N. Burgel, M. Fromm, et al. 2005. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 129: 550-564.
20. Epple, H. J., T. Schneider, H. Troeger, D. Kunkel, K. Allers, V. Moos, M. Amasheh, C. Loddenkemper, M. Fromm, M. Zeitz, and J. D. Schulzke. 2009. Impairment of the intestinal barrier is evident in untreated but absent in suppressively treated HIV-infected patients. Gut 58: 220-227.
21. Szakal, D. N., H. Gyorffy, A. Arato, A. Cseh, K. Molnar, M. Papp, A. Dezsofi, and G. Veres. 2010. Mucosal expression of claudins 2, 3 and 4 in proximal and distal part of duodenum in children with coeliac disease. Virchows Arch. 456: 245-250.
22. Ahmad, R., R. Chaturvedi, D. Olivares-Villagómez, T. Habib, M. Asim, P. Shivesh, D. B. Polk, K. T. Wilson, M. K. Washington, L. Van Kaer, et al. 2014. Targeted colonic claudin-2 expression renders resistance to epithelial injury, induces immune suppression, and protects from colitis. Mucosal Immunol. 7: 1340-1353.
23. Dudakov, J. A., A. M. Hanash, and M. R. van den Brink. 2015. Interleukin-22: immunobiology and pathology. Annu. Rev. Immunol. 33: 747-785.
24. Duhen, T., R. Geiger, D. Jarrossay, A. Lanzavecchia, and F. Sallusto. 2009. Production of interleukin 22 but not interleukin 17 by a subset of human skinhoming memory T cells. Nat. Immunol. 10: 857-863.
25. Trifari, S., C. D. Kaplan, E. H. Tran, N. K. Crellin, and H. Spits. 2009. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat. Immunol. 10: 864-871.
26. Martin, B., K. Hirota, D. J. Cua, B. Stockinger, and M. Veldhoen. 2009. Interleukin-17-producing gammadelta T cells selectively expand in response to pathogen products and environmental signals. Immunity 31: 321-330.
27. Sutton, C. E., S. J. Lalor, C. M. Sweeney, C. F. Brereton, E. C. Lavelle, and K. H. Mills. 2009. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity 31: 331-341.
28. Cella, M., A. Fuchs, W. Vermi, F. Facchetti, K. Otero, J. K. Lennerz, J. M. Doherty, J. C. Mills, and M. Colonna. 2009. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 457: 722-725.
29. Spits, H., D. Artis, M. Colonna, A. Diefenbach, J. P. Di Santo, G. Eberl, S. Koyasu, R. M. Locksley, A. N. McKenzie, R. E. Mebius, et al. 2013. Innate lymphoid cells-A proposal for uniform nomenclature. Nat. Rev. Immunol. 13: 145-149.
30. Wolk, K., S. Kunz, E. Witte, M. Friedrich, K. Asadullah, and R. Sabat. 2004. IL-22 increases the innate immunity of tissues. Immunity 21: 241-254.
31. Xie, M. H., S. Aggarwal, W. H. Ho, J. Foster, Z. Zhang, J. Stinson, W. I. Wood, A. D. Goddard, and A. L. Gurney. 2000. Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R. J. Biol. Chem. 275: 31335-31339.
32. Kotenko, S. V., L. S. Izotova, O. V. Mirochnitchenko, E. Esterova, H. Dickensheets, R. P. Donnelly, and S. Pestka. 2001. Identification of the functional interleukin-22 (IL-22) receptor complex: the IL-10R2 chain (IL-10Rbeta ) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes. J. Biol. Chem. 276: 2725-2732.
33. Lejeune, D., L. Dumoutier, S. Constantinescu, W. Kruijer, J. J. Schuringa, and J. C. Renauld. 2002. Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J. Biol. Chem. 277: 33676-33682.
34. Andoh, A., Z. Zhang, O. Inatomi, S. Fujino, Y. Deguchi, Y. Araki, T. Tsujikawa, K. Kitoh, S. Kim-Mitsuyama, A. Takayanagi, et al. 2005. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology 129: 969-984.
35. Sekikawa, A., H. Fukui, K. Suzuki, T. Karibe, S. Fujii, K. Ichikawa, S. Tomita, J. Imura, K. Shiratori, T. Chiba, and T. Fujimori. 2010. Involvement of the IL-22/ REG Ialpha axis in ulcerative colitis. Lab. Invest. 90: 496-505.
36. Sabat, R., W. Ouyang, and K. Wolk. 2014. Therapeutic opportunities of the IL-22-IL-22R1 system. Nat. Rev. Drug Discov. 13: 21-38.
37. Kamanaka, M., S. Huber, L. A. Zenewicz, N. Gagliani, C. Rathinam, W. O'Connor, Jr., Y. Y. Wan, S. Nakae, Y. Iwakura, L. Hao, and R. A. Flavell. 2011. Memory/effector (CD45RB(lo)) CD4 T cells are controlled directly by IL-10 and cause IL-22-dependent intestinal pathology. J. Exp. Med. 208: 1027-1040.
38. Jumarie, C., and C. Malo. 1991. Caco-2 cells cultured in serum-free medium as a model for the study of enterocytic differentiation in vitro. J. Cell. Physiol. 149: 24-33.
39. Al-Sadi, R., S. Guo, D. Ye, K. Dokladny, T. Alhmoud, L. Ereifej, H. M. Said, and T. Y. Ma. 2013. Mechanism of IL-1b modulation of intestinal epithelial barrier involves p38 kinase and activating transcription factor-2 activation. J. Immunol. 190: 6596-6606.
40. Gracz, A. D., B. J. Puthoff, and S. T. Magness. 2012. Identification, isolation, and culture of intestinal epithelial stem cells from murine intestine. Methods Mol. Biol. 879: 89-107.
41. Pham, T. A., S. Clare, D. Goulding, J. M. Arasteh, M. D. Stares, H. P. Browne, J. A. Keane, A. J. Page, N. Kumasaka, L. Kane, et al; Sanger Mouse Genetics Project. 2014. Epithelial IL-22RA1-mediated fucosylation promotes intestinal colonization resistance to an opportunistic pathogen. Cell Host Microbe 16: 504-516.
42. Pickert, G., C. Neufert, M. Leppkes, Y. Zheng, N. Wittkopf, M. Warntjen, H. A. Lehr, S. Hirth, B. Weigmann, S. Wirtz, et al. 2009. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J. Exp. Med. 206: 1465-1472.
43. Dumoutier, L., D. Lejeune, D. Colau, and J. C. Renauld. 2001. Cloning and characterization of IL-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor/IL-22. J. Immunol. 166: 7090-7095.
44. Xu, W., S. R. Presnell, J. Parrish-Novak, W. Kindsvogel, S. Jaspers, Z. Chen, S. R. Dillon, Z. Gao, T. Gilbert, K. Madden, et al. 2001. A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist. Proc. Natl. Acad. Sci. USA 98: 9511-9516.
45. Kotenko, S. V., L. S. Izotova, O. V. Mirochnitchenko, E. Esterova, H. Dickensheets, R. P. Donnelly, and S. Pestka. 2001. Identification, cloning, and characterization of a novel soluble receptor that binds IL-22 and neutralizes its activity. J. Immunol. 166: 7096-7103.
46. Bertiaux-Vandaële, N., S. B. Youmba, L. Belmonte, S. Lecleire, M. Antonietti, G. Gourcerol, A. M. Leroi, P. Déchelotte, J. F. Ménard, P. Ducrotté, and M. Coëffier. 2011. The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype. Am. J. Gastroenterol. 106: 2165-2173.
47. González-Mariscal, L., A. Betanzos, P. Nava, and B. E. Jaramillo. 2003. Tight junction proteins. Prog. Biophys. Mol. Biol. 81: 1-44.
48. Suzuki, T., N. Yoshinaga, and S. Tanabe. 2011. Interleukin-6 (IL-6) regulates claudin-2 expression and tight junction permeability in intestinal epithelium. J. Biol. Chem. 286: 31263-31271.
49. Al-Sadi, R., D. Ye, M. Boivin, S. Guo, M. Hashimi, L. Ereifej, and T. Y. Ma. 2014. Interleukin-6 modulation of intestinal epithelial tight junction permeability is mediated by JNK pathway activation of claudin-2 gene. PLoS One 9: e85345.
50. Weber, C. R., D. R. Raleigh, L. Su, L. Shen, E. A. Sullivan, Y. Wang, and J. R. Turner. 2010. Epithelial myosin light chain kinase activation induces mucosal interleukin-13 expression to alter tight junction ion selectivity. J. Biol. Chem. 285: 12037-12046.
51. Kinugasa, T., T. Sakaguchi, X. Gu, and H. C. Reinecker. 2000. Claudins regulate the intestinal barrier in response to immune mediators. Gastroenterology 118: 1001-1011.
52. Amoozadeh, Y., Q. Dan, J. Xiao, F. Waheed, and K. Szászi. 2015. Tumor necrosis factor-A induces a biphasic change in claudin-2 expression in tubular epithelial cells: role in barrier functions. Am. J. Physiol. Cell Physiol. 309: C38-C50.
53. Mankertz, J., M. Amasheh, S. M. Krug, A. Fromm, S. Amasheh, B. Hillenbrand, S. Tavalali, M. Fromm, and J. D. Schulzke. 2009. TNFalpha up-regulates claudin-2 expression in epithelial HT-29/B6 cells via phosphatidylinositol-3-kinase signaling. Cell Tissue Res. 336: 67-77.
54. Amasheh, S., N. Meiri, A. H. Gitter, T. Schöneberg, J. Mankertz, J. D. Schulzke, and M. Fromm. 2002. Claudin-2 expression induces cation-selective channels in tight junctions of epithelial cells. J. Cell Sci. 115: 4969-4976.
55. Pedranzini, L., T. Dechow, M. Berishaj, R. Comenzo, P. Zhou, J. Azare, W. Bornmann, and J. Bromberg. 2006. Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells. Cancer Res. 66: 9714-9721.
56. McFarland, B. C., J. Y. Ma, C. P. Langford, G. Y. Gillespie, H. Yu, Y. Zheng, S. E. Nozell, D. Huszar, and E. N. Benveniste. 2011. Therapeutic potential of AZD1480 for the treatment of human glioblastoma. Mol. Cancer Ther. 10: 2384-2393.
57. Rutz, S., X. Wang, and W. Ouyang. 2014. The IL-20 subfamily of cytokines-from host defence to tissue homeostasis. Nat. Rev. Immunol. 14: 783-795.
58. Brand, S., F. Beigel, T. Olszak, K. Zitzmann, S. T. Eichhorst, J. M. Otte, H. Diepolder, A. Marquardt, W. Jagla, A. Popp, et al. 2006. IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G827-G838.
59. Das, P., P. Goswami, T. K. Das, T. Nag, V. Sreenivas, V. Ahuja, S. K. Panda, S. D. Gupta, and G. K. Makharia. 2012. Comparative tight junction protein expressions in colonic Crohn's disease, ulcerative colitis, and tuberculosis: a new perspective. Virchows Arch. 460: 261-270.
60. Lindemans, C. A., M. Calafiore, A. M. Mertelsmann, M. H. O'Connor, J. A. Dudakov, R. R. Jenq, E. Velardi, L. F. Young, O. M. Smith, G. Lawrence, et al. 2015. Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration. Nature 528: 560-564.
61. Mizuno, S., Y. Mikami, N. Kamada, T. Handa, A. Hayashi, T. Sato, K. Matsuoka, M. Matano, Y. Ohta, A. Sugita, et al. 2014. Cross-talk between RORgt+ innate lymphoid cells and intestinal macrophages induces mucosal IL-22 production in Crohn's disease. Inflamm. Bowel Dis. 20: 1426-1434.
62. Mitra, A., S. K. Raychaudhuri, and S. P. Raychaudhuri. 2012. IL-22 induced cell proliferation is regulated by PI3K/Akt/mTOR signaling cascade. Cytokine 60: 38-42.
63. Ikeuchi, H., T. Kuroiwa, N. Hiramatsu, Y. Kaneko, K. Hiromura, K. Ueki, and Y. Nojima. 2005. Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine. Arthritis Rheum. 52: 1037-1046.
64. Monhasery, N., J. Moll, C. Cuman, M. Franke, L. Lamertz, R. Nitz, B. Görg, D. Häussinger, J. Lokau, D. M. Floss, et al. 2016. Transcytosis of IL-11 and apical redirection of gp130 is mediated by IL-11a receptor. Cell Reports 16: 1067-1081.
65. Tsai, P. Y., B. Zhang, W. Q. He, J. M. Zha, M. A. Odenwald, G. Singh, A. Tamura, L. Shen, A. Sailer, S. Yeruva, et al. 2017. IL-22 upregulates epithelial Claudin-2 to drive diarrhea and enteric pathogen clearance. Cell Host Microbe 21: 671-681.e674.
66. Sugimoto, K., A. Ogawa, E. Mizoguchi, Y. Shimomura, A. Andoh, A. K. Bhan, R. S. Blumberg, R. J. Xavier, and A. Mizoguchi. 2008. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J. Clin. Invest. 118: 534-544.
67. Yuki, T., M. Tobiishi, A. Kusaka-Kikushima, Y. Ota, and Y. Tokura. 2016. Impaired tight junctions in atopic dermatitis skin and in a skin-equivalent model treated with interleukin-17. PLoS One 11: e0161759.
68. Sands, B. E., J. Chen, B. G. Feagan, M. Penney, W. A. Rees, S. Danese, P. D. R. Higgins, P. Newbold, R. Faggioni, K. Patra, et al.2017. Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn's disease: a phase 2a study. Gastroenterology 153: 77-86.e76.